Injected Version of Eisai/Biogen Alzheimer’s Drug Works as Well as IV Leqembi

On 26 October 2023, Eisai and Biogen’s Alzheimer’s drug, Leqembi, was found to be as effective as the current intravenous administration in removing toxic brain plaques. However, the review conducted by the drugmakers revealed that the rates of serious side effects were higher when using the drug in its subcutaneous injection form. The company’s analysis compared data from 72 early Alzheimer’s patients who received Leqembi through subcutaneous injection to prior pivotal trial results from 898 patients who received the drug via infusion.

During the presentation of the latest data at the Clinical Trials on Alzheimer’s Disease, it was revealed that after six months of treatment, the subcutaneous version of Leqembi removed 14% more amyloid plaques than the approved intravenous formulation. Additionally, blood concentration levels of the drug were 11% higher with the subcutaneous Leqembi compared to the intravenous version. Furthermore, the company’s conclusion was that the rates of side effects related to the infusion or injection were lower for the subcutaneous formulation, but the rates of serious side effects were higher.

According to Roots Analysis, the Alzheimer’s Market is estimated to be worth $7.6 billion in 2022 and is expected to grow at a CAGR of 12% during the forecast period.

For detailed insights about this domain, check out our report on Alzheimer’s Market or email

You may also be interested in the following titles: